An IL-10 agonist engineered to need TYK2 quiets myeloid cells and spares T cells in animals

Native IL-10 is a domain-swapped dimer that assembles a signalling complex with two copies each of IL-10R-alpha and IL-10R-beta. That lets JAK1 be activated by two routes, TYK2-JAK1 and JAK1-JAK1 transphosphorylation ^[8]. To pull the routes apart, the authors used VVD-118313, a selective allosteric JAK1 inhibitor that targets mouse C816 and blocks JAK1 transphosphorylation without inhibiting kinase domains ^[10].

The authors say the tetravalent format is what makes signalling strictly TYK2-dependent and highly sensitive to IL-10R-alpha and IL-10R-beta abundance, and that this gives the agonist its selective activity in myeloid cells ^[4]. Selectivity therefore rests on two conditions at once: the kinase route and the amount of receptor on the cell. The thing this doesn't tell you is how the receptor-abundance condition behaves in the inflamed gut, where the authors propose to use the drug ^[12].

In our view the primate durability is the most informative result here. Earlier attempts at selective IL-10 variants were constrained by short half-life, immunogenicity and incomplete separation of beneficial and harmful activities ^[9]. Myeloid suppression lasting up to 30 days with IgG-like kinetics speaks to the first problem ^[6]. The T cell and blood-count readouts in the same primates speak to the third. Immunogenicity is a separate question, and the abstract does not list it among the primate findings.

The condition on that view is the one every translation claim carries. Mouse colitis is an inflammatory bowel model, not a patient, and the primate readouts are about drug behaviour and safety. Whether the margin between myeloid suppression and T cell activation is wide enough in people is a clinical question.

The text we have stops before the JAK1 inhibitor results and does not report group sizes, doses or effect sizes, so the width of that margin in the animal data cannot yet be judged.